ACTOS (pioglitazone HCl) halted progression of atherosclerosis as indicated by CIMT
Researchers today presented data showing that ACTOS (pioglitazone HCl) halted the progression of atherosclerosis as measured by carotid intima-media thickness (CIMT) in patients with type 2 diabetes. Results from the clinical trial, CHICAGO (Carotid intima-media thickness in Atherosclerosis using pioglitazone), are part of a late-breaker presentation at the American Heart Association’s Scientific Sessions 2006, coincidentally being held in Chicago, and coincide with an early online issue of the Journal of the American Medical Association.